for the identification of superior antibody therapeutics
J.HALSM is a revolutionary AI-driven discovery platform, producing diverse human antibodies with broad efficacy features biased toward developability, enabling rapid entry and success in the clinic. Using generative adversarial networks (GANs), J.HAL offers a new class of AI-derived antibodies – optimized for development, manufacturing, and in-use characteristics – better suited as biotherapeutics.
A highly efficient starting point for drug discovery and development projects across a broad range of indications.
The J.HAL Difference
- Fully human antibodies with broad diversity
- Designed and sequence-biased in silico for superior efficacy, efficiency, and developability features
- Lead discovery with decreased time and cost
Antibodies discovered with J.HAL can benefit from all of the integrated services of Just – Evotec Biologic’s J.DESIGN technology platform for biotherapeutic development
|Antibody Attribute||In Vivo Approaches||Traditional Libraries||J.HAL℠ Library|
|Description||Evolved for affinity||Designed for diversity in CDRs||Designed for diversity, humanness, and developability|